Ovid Therapeutics Stock Net Income
| OVID Stock | USD 1.69 0.06 3.43% |
As of the 25th of January, Ovid Therapeutics holds the Risk Adjusted Performance of 0.0401, coefficient of variation of 2334.52, and Semi Deviation of 4.38. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Ovid Therapeutics, as well as the relationship between them. Please check Ovid Therapeutics information ratio, as well as the relationship between the value at risk and expected short fall to decide if Ovid Therapeutics is priced some-what accurately, providing market reflects its current price of 1.69 per share. Please also confirm Ovid Therapeutics total risk alpha, which is currently at (0.30) to check out the company can sustain itself at a future point.
Ovid Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Ovid Therapeutics' valuation are provided below:Ovid Therapeutics does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ovid Therapeutics. If investors know Ovid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ovid Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ovid Therapeutics is measured differently than its book value, which is the value of Ovid that is recorded on the company's balance sheet. Investors also form their own opinion of Ovid Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Ovid Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ovid Therapeutics' market value can be influenced by many factors that don't directly affect Ovid Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ovid Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ovid Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Ovid Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ovid Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ovid Therapeutics.
| 10/27/2025 |
| 01/25/2026 |
If you would invest 0.00 in Ovid Therapeutics on October 27, 2025 and sell it all today you would earn a total of 0.00 from holding Ovid Therapeutics or generate 0.0% return on investment in Ovid Therapeutics over 90 days. Ovid Therapeutics is related to or competes with Context Therapeutics, MacroGenics, Clene, Oramed Pharmaceuticals, Shattuck Labs, ImageneBio, and Connect Biopharma. Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurolo... More
Ovid Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ovid Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ovid Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.98 | |||
| Information Ratio | 0.0293 | |||
| Maximum Drawdown | 29.07 | |||
| Value At Risk | (7.30) | |||
| Potential Upside | 9.2 |
Ovid Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ovid Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ovid Therapeutics' standard deviation. In reality, there are many statistical measures that can use Ovid Therapeutics historical prices to predict the future Ovid Therapeutics' volatility.| Risk Adjusted Performance | 0.0401 | |||
| Jensen Alpha | 0.2105 | |||
| Total Risk Alpha | (0.30) | |||
| Sortino Ratio | 0.0341 | |||
| Treynor Ratio | 0.5919 |
Ovid Therapeutics January 25, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0401 | |||
| Market Risk Adjusted Performance | 0.6019 | |||
| Mean Deviation | 4.07 | |||
| Semi Deviation | 4.38 | |||
| Downside Deviation | 4.98 | |||
| Coefficient Of Variation | 2334.52 | |||
| Standard Deviation | 5.79 | |||
| Variance | 33.52 | |||
| Information Ratio | 0.0293 | |||
| Jensen Alpha | 0.2105 | |||
| Total Risk Alpha | (0.30) | |||
| Sortino Ratio | 0.0341 | |||
| Treynor Ratio | 0.5919 | |||
| Maximum Drawdown | 29.07 | |||
| Value At Risk | (7.30) | |||
| Potential Upside | 9.2 | |||
| Downside Variance | 24.81 | |||
| Semi Variance | 19.19 | |||
| Expected Short fall | (5.50) | |||
| Skewness | 0.9757 | |||
| Kurtosis | 2.63 |
Ovid Therapeutics Backtested Returns
Ovid Therapeutics appears to be extremely dangerous, given 3 months investment horizon. Ovid Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of 0.0428, which implies the firm had a 0.0428 % return per unit of risk over the last 3 months. We have found thirty technical indicators for Ovid Therapeutics, which you can use to evaluate the volatility of the company. Please evaluate Ovid Therapeutics' Coefficient Of Variation of 2334.52, risk adjusted performance of 0.0401, and Semi Deviation of 4.38 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Ovid Therapeutics holds a performance score of 3. The company holds a Beta of 0.4, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Ovid Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Ovid Therapeutics is expected to be smaller as well. Please check Ovid Therapeutics' total risk alpha, expected short fall, market facilitation index, as well as the relationship between the value at risk and daily balance of power , to make a quick decision on whether Ovid Therapeutics' historical price patterns will revert.
Auto-correlation | -0.21 |
Weak reverse predictability
Ovid Therapeutics has weak reverse predictability. Overlapping area represents the amount of predictability between Ovid Therapeutics time series from 27th of October 2025 to 11th of December 2025 and 11th of December 2025 to 25th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ovid Therapeutics price movement. The serial correlation of -0.21 indicates that over 21.0% of current Ovid Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.21 | |
| Spearman Rank Test | 0.11 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Ovid Therapeutics reported net income of (26.43 Million). This is 107.75% lower than that of the Biotechnology sector and 137.74% lower than that of the Health Care industry. The net income for all United States stocks is 104.63% higher than that of the company.
Ovid Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ovid Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ovid Therapeutics could also be used in its relative valuation, which is a method of valuing Ovid Therapeutics by comparing valuation metrics of similar companies.Ovid Therapeutics is currently under evaluation in net income category among its peers.
Ovid Fundamentals
| Return On Equity | -0.6 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (94.87) % | |||
| Current Valuation | 108.51 M | |||
| Shares Outstanding | 71.21 M | |||
| Shares Owned By Insiders | 9.81 % | |||
| Shares Owned By Institutions | 33.51 % | |||
| Number Of Shares Shorted | 4.38 M | |||
| Price To Earning | 1.11 X | |||
| Price To Book | 2.69 X | |||
| Price To Sales | 18.21 X | |||
| Revenue | 566 K | |||
| Gross Profit | 6.61 M | |||
| EBITDA | (57.77 M) | |||
| Net Income | (26.43 M) | |||
| Cash And Equivalents | 152.37 M | |||
| Cash Per Share | 2.16 X | |||
| Total Debt | 14.76 M | |||
| Debt To Equity | 0.10 % | |||
| Current Ratio | 16.94 X | |||
| Book Value Per Share | 0.63 X | |||
| Cash Flow From Operations | (55.96 M) | |||
| Short Ratio | 2.70 X | |||
| Earnings Per Share | (0.50) X | |||
| Target Price | 4.05 | |||
| Number Of Employees | 23 | |||
| Beta | 0.22 | |||
| Market Capitalization | 120.35 M | |||
| Total Asset | 92.17 M | |||
| Retained Earnings | (304.3 M) | |||
| Working Capital | 45.42 M | |||
| Current Asset | 74.21 M | |||
| Current Liabilities | 5.13 M | |||
| Net Asset | 92.17 M |
About Ovid Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ovid Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ovid Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ovid Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ovid Therapeutics is a strong investment it is important to analyze Ovid Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ovid Therapeutics' future performance. For an informed investment choice regarding Ovid Stock, refer to the following important reports:Check out Ovid Therapeutics Piotroski F Score and Ovid Therapeutics Altman Z Score analysis. For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ovid Therapeutics. If investors know Ovid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ovid Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ovid Therapeutics is measured differently than its book value, which is the value of Ovid that is recorded on the company's balance sheet. Investors also form their own opinion of Ovid Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Ovid Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ovid Therapeutics' market value can be influenced by many factors that don't directly affect Ovid Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ovid Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ovid Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.